Mike E. Platt

BlueCrest Capital Management Ltd. (BlueCrest) is a single-family office headquartered in St. Helier, UK. They are a subsidiary of WHR Investments Ltd., ultimately owned by BC Cayman Charitable Trust in Cayman Islands. The firm was previously a hedge fund management firm and in 2015, Michael Platt decided to turn BlueCrest into a firm that only managed his own money and money that belongs to BlueCrest partners and employees.

Engitix Ltd. is a preclinical stage biopharma British company that is developing breakthrough therapies for fibrosis and solid tumors using its patient-centric human extracellular matrix drug discovery platform. The company has drug discovery partnerships with Dompe Farmaceutici and Takeda for advanced fibrotic liver diseases and fibrostenotic inflammatory bowel disease. Engitix was established in 2016 to commercialize research from the Institute for Liver and Digestive Health at University College London. The company is headquartered in WestWorks, London, UK. Giuseppe Mazza and Massimo Pinzani founded the company, and Giuseppe Mazza has been the CEO since 2016.

BC Capital Management Services Ltd. operates as an alternative investment manager. The company was founded in 2000 and is headquartered in London, the United Kingdom.

BlueCrest Capital Management (UK) LLP (BCM-UK) is an independent, Great Britain-based alternative asset management firm headquartered in London. The firm was founded in 2009 by Michael Platt and Bill Reeves to manage their flagship fund, BlueCrest Capital International. In 2015, they transitioned to a Private Investment Partnership and returned client capital. BCM-UK currently manages assets solely on behalf of their partners and employees.